H2 antagonist Rx-to-OTC switch saves $500,000 in managed care setting.
This article was originally published in The Tan Sheet
Executive Summary
H2 ANTAGONIST Rx-TO-OTC SWITCH IN MCO SETTING SAVES $500,000 in half a year, Diversified Pharmaceutical Services Regional Director of Clinical Programs Scott Enos reported at the American Managed Care Pharmacy annual meeting in Philadelphia May 1-2. The DPS program, which mandated the use of OTC H2s in place of low-dose, but not high-dose, Rx acid blockers for ulcer treatment in a managed care organization, "demonstrated a 50% decrease in per member per month (PMPM) cost and a 10% decrease in utilization" of the H2 antagonist, according to Enos. The decreases resulted in an "estimated savings of over $500,000 in the first five months."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning